Mysoline: Advanced Seizure Control with Established Efficacy

Mysoline

Price from 35.26 $

Show more

Product dosage: 250 mg
Package (num)	Per tab	Price	Buy
30	$1.18	$35.26 (0%)	🛒 Add to cart
60	$0.92	$70.52 $55.04 (22%)	🛒 Add to cart
90	$0.87	$105.78 $78.26 (26%)	🛒 Add to cart
120	$0.79	$141.04 $94.60 (33%)	🛒 Add to cart
180	$0.74	$211.56 $133.30 (37%)	🛒 Add to cart
360	$0.66 Best per tab	$423.12 $236.50 (44%)	🛒 Add to cart
Synonyms Primidone

Mysoline (primidone) is a time-tested anticonvulsant medication prescribed for the management of various seizure disorders. As a barbiturate derivative, it exerts its therapeutic effect by decreasing abnormal electrical activity in the brain, thereby stabilizing neuronal membranes and raising the seizure threshold. Its long history of clinical use provides a robust profile of efficacy and a well-understood safety spectrum, making it a cornerstone option in comprehensive neurological treatment plans for both partial and generalized tonic-clonic seizures. This medication represents a critical tool for neurologists aiming to achieve and maintain long-term seizure freedom for their patients.

Features

• Active Pharmaceutical Ingredient: Primidone
• Therapeutic Class: Anticonvulsant, Barbiturate derivative
• Available Formulations: Oral tablets (50 mg, 250 mg) and oral suspension
• Mechanism of Action: Modulates GABA-A receptor function, suppresses neuronal excitability
• Bioavailability: High, with rapid absorption from the gastrointestinal tract
• Metabolism: Hepatic, via cytochrome P450 system into active metabolites (phenobarbital, phenylethylmalonamide)
• Half-life: Primidone: 5-18 hours; Primary active metabolite (Phenobarbital): 53-140 hours

Benefits

• Provides robust and reliable control of motor seizures, reducing both frequency and severity.
• Offers a long-standing clinical record, allowing for predictable patient response and well-documented management strategies.
• Effective as both monotherapy and adjunctive therapy, offering flexibility in treatment regimens.
• Contributes to improved quality of life by enabling greater daily functioning and reducing the fear of seizure occurrence.
• The presence of active metabolites with long half-lives can contribute to sustained 24-hour seizure protection.

Common use

Mysoline is primarily indicated for the control of grand mal (generalized tonic-clonic), psychomotor (complex partial), and focal epileptic seizures. It may be used as a first-line agent or introduced when other anticonvulsants have proven ineffective or intolerable. Its use is also well-documented in the treatment of essential tremor, providing symptomatic relief for this movement disorder. Treatment is always initiated and monitored by a neurologist or a physician specializing in seizure disorders.

Dosage and direction

Dosage is highly individualized based on the patient’s age, clinical response, renal and hepatic function, and concomitant medications. Therapy is typically initiated at a low dose to minimize initial side effects and gradually titrated upward.

• Adults and children over 8 years: Treatment often begins with 100-125 mg at bedtime for the first 3 days. The dose is then gradually increased by 100-125 mg every 3 days until a maintenance dose is achieved, typically ranging from 750 mg to 1.5 g per day, administered in divided doses (2-4 times daily).
• Children under 8 years: Initial dose is typically 50 mg at bedtime for the first 3 days, with gradual increases of 50 mg every 3 days to a usual maintenance dose of 10-25 mg/kg/day in divided doses.
• Administration: Tablets should be swallowed whole with a full glass of water. The oral suspension must be shaken vigorously for at least 30 seconds before each use. It can be taken with or without food, but consistency is key to maintaining stable blood levels.

Precautions

Patients should be closely monitored by their physician throughout therapy. The following precautions are essential:

• Hematologic Monitoring: Periodic complete blood counts should be performed, as primidone has been associated with megaloblastic anemia that may respond to folic acid therapy.
• Hepatic and Renal Function: Use with extreme caution in patients with impaired liver or kidney function, as this can alter drug metabolism and excretion, leading to accumulation and toxicity. Dosage adjustments are mandatory.
• Suicidal Ideation: Antiepileptic drugs, including Mysoline, increase the risk of suicidal thoughts and behavior. Patients, their caregivers, and families should be alert to the emergence or worsening of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts.
• Dependence and Withdrawal: Prolonged use can lead to physical and psychological dependence. Abrupt discontinuation may precipitate status epilepticus or severe withdrawal symptoms. Dosage must be tapered gradually under medical supervision.
• Porphyria: Mysoline is contraindicated in patients with porphyria as it can precipitate acute attacks.
• Elderly Patients: This population may exhibit increased sensitivity to the drug’s effects (e.g., drowsiness, ataxia) and often requires slower titration and lower maintenance doses.

Contraindications

Mysoline is contraindicated in patients with:

• Known hypersensitivity to primidone or any component of the formulation, or to phenobarbital.
• A history of porphyria.
• Significant respiratory depression or severe obstructive sleep apnea.
• Severe hepatic impairment.

Possible side effect

Side effects are often dose-related and may diminish with continued use or dosage adjustment. Common side effects include:

• Very Common (>10%): Ataxia (loss of coordination), dizziness, drowsiness, fatigue, nausea, vomiting.
• Common (1-10%): Anorexia, diplopia (double vision), nystagmus, irritability, emotional disturbances.
• Uncommon (0.1-1%): Skin rashes, sexual dysfunction, arthralgia.
• Rare (<0.1%): Hematologic reactions (e.g., leukopenia, thrombocytopenia, agranulocytosis), systemic lupus erythematosus, lymphadenopathy.

Patients should report any persistent or severe side effects to their physician immediately.

Drug interaction

Mysoline has a significant potential for drug interactions due to its potent induction of hepatic enzymes (CYP450 system).

• Enhanced Sedation: Concomitant use with other CNS depressants (alcohol, benzodiazepines, opioids, sedating antihistamines) can result in profound sedation, respiratory depression, coma, or death.
• Reduced Efficacy of Other Drugs: Mysoline can accelerate the metabolism of numerous medications, reducing their plasma levels and effectiveness. This includes: oral anticoagulants (e.g., warfarin), corticosteroids, oral contraceptives, beta-blockers, tricyclic antidepressants, cyclosporine, and many other anticonvulsants (e.g., lamotrigine, valproate, carbamazepine).
• Increased Mysoline Levels: Valproic acid and isoniazid can inhibit the metabolism of primidone/phenobarbital, leading to increased levels and potential toxicity.
• Other Anticonvulsants: Complex interactions can occur when used with phenytoin or carbamazepine, often requiring careful therapeutic drug monitoring.

A comprehensive review of all medications (prescription, OTC, and herbal) with a physician is imperative.

Missed dose

• If a dose is missed, it should be taken as soon as it is remembered.
• However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should never take a double dose to make up for a forgotten one.
• Maintaining a consistent dosing schedule is critical for stable seizure control.

Overdose

Overdose is a medical emergency characterized primarily by profound CNS depression.

• Symptoms: Severe drowsiness progressing to coma, hypothermia, respiratory depression, hypotension, and diminished reflexes.
• Treatment: Requires immediate hospitalization. Management is supportive and includes securing the airway, assisted ventilation, and maintaining blood pressure. Gastric lavage may be considered if presentation is early. Hemodialysis may be beneficial due to the drug’s relatively low volume of distribution. There is no specific antidote.

Storage

• Store at room temperature (20°-25°C or 68°-77°F) in a tight, light-resistant container.
• Keep the bottle tightly closed and protect from moisture.
• Keep out of reach of children and pets.
• Do not use after the expiration date printed on the packaging.
• Safely dispose of any unused medication via a drug take-back program.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author does not recommend or endorse any specific tests, physicians, products, or procedures.

Reviews

“After struggling with partial seizures that were poorly controlled on two other medications, my neurologist introduced Mysoline. The initial drowsiness was challenging, but after a slow titration, we found my effective dose. I have now been seizure-free for over 18 months, which has been life-changing. The consistency is key.” – M.K., 42

“As a caregiver for my elderly father with essential tremor, the difference after starting a low dose of Mysoline was remarkable. His handwriting became legible again, and he could drink without spilling. We monitor him closely for drowsiness, but the benefit to his daily independence has been immense.” – J.L., 55

“My son has had generalized tonic-clonic seizures since childhood. We’ve been on a cocktail of drugs, but Mysoline has been the most consistent in keeping the major episodes at bay. The therapeutic drug monitoring gives us confidence that we are within the effective range. It’s a powerful drug that requires respect and careful management.” – Parent of a patient, 16